Breaking News, Financial News

Genzyme Corp.

Plant shutdown takes a toll on revenues, demolishes earnings

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genzyme Corp. 2Q10 2Q Revenues: $1.1 billion (-12%) 2Q Earnings: $23,000 (-99.9%) YTD Revenues: $2.2 billion (-9%) YTD Loss: $115 million (income of $383 million in YTD09) Comments: Cerezyme (-53%) and Fabrazyme (-71%) sales plummeted in 2Q10 as manufacturing woes at Genzyme’s Allston, MA facility restricted supply. Myozyme sales rose 16% to $92 million. Genzyme took a $22 million charge in the quarter primarily to write off unusable material. The company will transfer fill/...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters